Diagnosis and Treatment of Neuroendocrine Tumors
Presented by Joseph Pisegna, MD, J. Randolph Hecht, MD, Ken Hermann, MD, and Timothy R. Donahue, MD, PhD
About the Lecture
Neuroendocrine tumors (NETS) comprise both carcinoid tumors and pancreatic islet cell tumors. NETs are becoming increasingly diagnosed because of improved imaging techniques and greater public awareness. The diagnosis and management of NETs is best accomplished using a multidisciplinary team approach that involves close interaction between oncologists, gastroenterologists, radiologists, surgeons and nuclear medicine. This interdisciplinary team of physician-scientists review the clinical presentation of NETs as well as the role of diagnostic imaging methods to identify the location and stage of disease. They review the surgical and endoscopic approaches to treatment as well as the role of hormonal and chemotherapy including targeted chemotherapies. This program provide greater awareness of the clinical features of NETs and introduces the lay public to UCLA’s NET Program.
About the Speakers
Joseph Pisegna, MD is a Professor of Medicine Professor of Medicine and Human Genetics at UCLA and Chief of the Division of Gastroenterology and Hepatology at the VA Greater Los Angeles Healthcare System. Dr. Pisegna is interested in the molecular pharmacology of hormones and receptors in the gastrointestinal tract, especially the diagnosis and management of islet cell tumors of the pancreas. His research and clinical interests derive from research in the biochemistry and physiology of neuroendocrine tumors. His addition to the faculty of the UCLA Center for Pancreatic Diseases provides unsurpassed expertise in the diagnosis and medical management of pancreatic endocrine tumors.
Timothy R. Donahue, MD is an Associate Professor of Surgery and Molecular & Medical Pharmacology at the David Geffen School of Medicine at UCLA. He is the Director of the Pancreatic Translational Program at the UCLA Institute for Molecular Medicine. His clinical practice is focused on pancreatic surgery, and his research program examines the molecular genetics of pancreatic cancer.
J. Randolph Hecht, MD is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies.
Ken Herrmann, MD, is an Associate Professor in the Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA. He graduated from Charité in Berlin (Germany) in 2004 and was trained in nuclear medicine in Munich. He has been at UCLA since 2011. In addition, he serves as Chair of Nuclear Medicine at Universitätsklinikum Essen, Germany. His research focuses on radionuclide theranostics especially in neuroendocrine tumors.